The clinical significance of MYC and BCL2 genetic alterations in diffuse large B-cell
lymphoma (DLBCL), apart from translocations, has not been comprehensively investigated …

Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …

Genomic alterations and protein expression levels have been established as prognostic
factors for survival in patients with diffuse large B‐cell lymphoma (DLBCL). In particular …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease whose prognosis is
associated with clinical features, cell-of-origin and genetic aberrations. Recent integrative …

MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and
confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and …

Purpose To explore the prognostic impact and interdependence of the cell-of-origin (COO)
classification, dual expression (DE) of MYC and BCL2 proteins, and MYC, BCL2, and BCL6 …

Purpose: Diffuse large B-cell lymphoma (DLBCL) is molecularly and clinically
heterogeneous, and can be subtyped according to genetic alterations, cell-of-origin, or …

Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to
cell-of-origin: data from the phase III GOYA study - PMC Back to Top Skip to main content NIH …

Background Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B …

To gain insight into the genomic basis of diffuse large B-cell lymphoma (DLBCL), we
performed massively parallel whole-exome sequencing of 55 primary tumor samples from …